KEYMED BIOSCIENCES -0001 (F:64Z) — Market Cap & Net Worth
Market Cap & Net Worth: KEYMED BIOSCIENCES -0001 (64Z)
KEYMED BIOSCIENCES -0001 (F:64Z) has a market capitalization of $2.28 Billion (€1.95 Billion) as of August 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #5672 globally and #889 in its home market, demonstrating a -11.54% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying KEYMED BIOSCIENCES -0001's stock price €8.05 by its total outstanding shares 294599566 (294.60 Million). Review total liabilities of KEYMED BIOSCIENCES -0001 to assess the company's total debt and financial obligations.
KEYMED BIOSCIENCES -0001 Market Cap History: 2022 to 2026
KEYMED BIOSCIENCES -0001's market capitalization history from 2022 to 2026. Data shows growth from $2.08 Billion to $2.77 Billion (31.87% CAGR).
KEYMED BIOSCIENCES -0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how KEYMED BIOSCIENCES -0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.69x
KEYMED BIOSCIENCES -0001's market cap is 2.69 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $2.08 Billion | $100.06 Million | -$308.12 Million | 20.82x | N/A |
| 2023 | $1.88 Billion | $354.10 Million | -$359.36 Million | 5.30x | N/A |
| 2024 | $1.23 Billion | $428.12 Million | -$515.24 Million | 2.86x | N/A |
| 2025 | $1.93 Billion | $716.31 Million | -$522.64 Million | 2.69x | N/A |
Competitor Companies of 64Z by Market Capitalization
Companies near KEYMED BIOSCIENCES -0001 in the global market cap rankings as of August 5, 2026.
Key companies related to KEYMED BIOSCIENCES -0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
KEYMED BIOSCIENCES -0001 Historical Marketcap From 2022 to 2026
Between 2022 and today, KEYMED BIOSCIENCES -0001's market cap moved from $2.08 Billion to $ 2.77 Billion, with a yearly change of 31.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.77 Billion | +43.75% |
| 2025 | €1.93 Billion | +57.30% |
| 2024 | €1.23 Billion | -34.68% |
| 2023 | €1.88 Billion | -9.92% |
| 2022 | €2.08 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of KEYMED BIOSCIENCES -0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.28 Billion USD |
| MoneyControl | $2.28 Billion USD |
| MarketWatch | $2.28 Billion USD |
| marketcap.company | $2.28 Billion USD |
| Reuters | $2.28 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About KEYMED BIOSCIENCES -0001
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China and internationally. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), chronic rhinosinusitis with nasal polyposis (CRSwNP), seasonal allergic rhinitis, prurigo nodula… Read more